Wilson’s disease, also known as hepatolenticular degeneration or progressive lenticular degeneration, is a rare genetic disorder caused by copper poisoning in the body. In a healthy body, the liver filters the excess copper and releases it through urine. The liver of a person suffering from Wilson’s disease cannot perform this function. Wilson’s disease is diagnosed by blood tests where abnormalities in liver enzymes, copper levels in the blood, lower levels of ceruloplasmin, a protein that carries copper through the blood, a mutated gene or low blood sugar. Treatment include oral drug containing zinc, d-penicillamine, Tetrathiomolybdate and trientine or syprine.
Get Sample Copy at: https://www.coherentmarketinsights.com/insight/request-sample/526
Increasing awareness regarding Wilson’s disease and its symptoms is expected to fuel the market of Wilson’s disease treatment market in the near future. Moreover, growing population all over the world is expected to boost the growth of Wilson’s disease market.
Rising incidence of Wilson’s disease is due to increase in the population worldwide as Wilson’s disease is a rare genetic disorder which, is expected to favor the demand for Wilson’s disease treatment market around the globe.
According to the European Association for the study of liver (EASL) in 2011 published that Wilson’s disease is a genetic disorder that is found worldwide and is recognized to be more common than previous, with a gene frequency of 1 in 90 -150 and an incidence that is 1 in 30,000 and more than 500 distinct mutations are described in the Wilson’s gene from which 380 have a confirmed role in the pathogenesis of the disease. Whereas, European Association also stated in year 2011 that Wilson’s disease accounts for 6 – 12% of all patient with acute liver failure who are referred for emergency transplantation.
Rapid advancements in technology allowing for early detection driving growth of the Wilson’s disease treatment market
North America accounts for the largest share in the global Wilson’s disease treatment market, followed by Europe. This is mainly attributed due to rapid growth in aging population in these regions. Asia Pacific is expected to emerge as a fast growing market for Wilson’s disease over the forecast period. Increasing population in China and India position these as highly lucrative markets for Wilson’s disease treatment. Increase in health expenditure on healthcare further fuels growth of Wilson’s disease treatment market in the region. The market is expected to show high growth rate in Asia Pacific region over the forecast period as Asia consist of 60% of the world’s current population and as Wilson’s disease is a hereditary disease the chance of expansion of this disease is more in Asia Pacific region. According to National Institute on Aging in 2010 it was estimated that 524 million people were aged 65 or older that is 8% of the world’s population and by 2050, which is expected to nearly triple the number to 1.5 billion, representing 16% of the world’s population. This above mentioned statistics is expected favor the growth of Wilson’s disease treatment market.
Increase in awareness regarding Wilson’s disease is expected to fuel the Wilson’s disease treatment market in near future
There are various organization and association working to create the awareness regarding Wilson’s disease for example, Wilson’s disease association is a volunteer organization striving to promote the well-being of the patients with Wilson’s disease where they offer the latest information about disease and its symptoms and treatment. Moreover Wilson’s disease association supports research and clinical investigation for Wilson’s disease.
Furthermore, manufacturers also significantly supports the Wilson’s disease awareness programs for example, in 2016, Valeant pharmaceutical announced company’s commitment to improve the lives of Wilson’s disease patients around the world, whereas Valeant has agreed to provide US$ 100,000 to fund enhanced patient awareness and research into the Wilson’s disease.
Buy Now This Report: https://www.coherentmarketinsights.com/insight/buy-now/526
Some major players operating in the Wilson’s disease treatment market are Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Wilson Therapeutics AB, Kadmon Holdings, Inc., Merck & Co., Inc., VHB Life Science Ltd., Teva Pharmaceuticals USA, Inc. and Tsumura & Co.
This post was originally published on Trading Herald